On February 17, 12-month data from the Personalized Anti-TNF therapy in Crohn’s disease...
- PANTS study supports infliximab biosimilar use for Crohn’s disease
- Can Takeda’s Entyvio Be a first-line biologic For UC treatment?
- Checkpoint inhibitors continue to show benefits in a range of tumours
- Back to the future: old antibiotic compounds offer new hope in the fight against antibiotic resistance
- Cancer cachexia trial design: lack of consensus on endpoints
GSK reports positive efficacy data of Fluarix Quadrivalent
GlaxoSmithKline (GSK) has reported positive results from a trial that examined the safety and efficacy of Fluarix Quadrivalent vaccine for the treatment of influenza in children aged six months through 35 months.
Aimmune reports positive results in PALISADE trial
Aimmune Therapeutics has reported that it has met its primary endpoint in a Phase III PALISADE trial, successfully evaluating the safety and efficacy of AR101 for the treatment of patients with a peanut allergy.
Vertex to start Phase III trial of VX-659, tezacaftor, and ivacaftor
Vertex Pharmaceuticals is set to initiate a Phase III trial of VX-659, tezacaftor, and ivacaftor as a triple combination regimen to treat people with cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation.
PANTS study supports infliximab biosimilar use for Crohn’s disease
On February 17, 12-month data from the Personalized Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organization (ECCO).
Can Takeda’s Entyvio Be a first-line biologic For UC treatment?
At the 13th Congress of the European Crohn’s and Colitis Organization (ECCO) – Inflammatory Bowel Diseases (IBD) in Vienna, Austria, which took place from February 14–17, Takeda announced real-world data that evaluated the effectiveness of Entyvio (vedolizumab) versus tumor necrosis factor (TNF) alpha inhibitors for patients suffering from moderate to severe ulcerative colitis (UC).
Nusinersen offers new hope for children with spinal muscular atrophy
A new medication has been shown to improve motor function in children with late-onset spinal muscular atrophy (SMA).
Celgene announces positive data for Behçet’s disease treatment
Celgene has released data from a Phase III trial for its drug Otezla (apremilast), a phosphodiesterase 4 (PDE4) inhibitor that is used in the treatment of Behçet's disease.
Vical begins Phase II trial of VL-2397 for invasive aspergillosis
Vical has started a Phase II trial to compare the efficacy and safety of VL-2397 to standard treatment for acute leukemia patients with invasive aspergillosis and recipients of an allogeneic hematopoietic cell transplant (HCT).
Medicines Company completes enrolment in Phase III trial of inclisiran
US-based Medicines Company has completed enrolling patients in a Phase III trial of inclisiran for treatment of heterozygous familial hypercholesterolemia patients.
AllTrials urges FDA to fine sponsors for missing trial results
AllTrials has called upon the US Food and Drug Administration (FDA) to impose fines up to $10,000 a day against clinical trial sponsors that fail to publish trial results on ClinicalTrials.gov.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.